01 — Initial screening
What the initial screening considered
A company needed more than an attractive website or a general “99% purity” statement to advance. Companies relying entirely on marketing statements, generic example reports, or COAs available only by private request were not treated the same as suppliers publishing batch-specific evidence.
- An active, accessible product catalog
- Publicly available COAs or laboratory reports
- Product and lot information that could be matched to the listing
- Identification of the testing laboratory
- Report numbers, QR codes, search codes, or another verification method
- Enough documentation to conduct a meaningful product-level audit
02 — Qualification
The strict COA standard
A product qualified only when its specific COA documented the complete evidence set. The information had to appear in the actual laboratory report. A product-page claim saying that testing was performed did not replace a missing result.
- Correct product or blend identification
- A visible batch or lot number
- A visible COA or report number
- Purity testing, normally by HPLC
- Measured peptide quantity or net content
- Heavy-metals screening
- Bacterial-endotoxin or comparable contamination screening
- Sterility testing
Reports showing only purity and identity were classified as incomplete, even when the reported purity was excellent.
03 — No blanket passes
Products qualified individually—not entire companies
A company was never given a blanket pass simply because one product had excellent testing. Each product was evaluated separately, so a company could have several qualifying products while other products from the same catalog remained excluded.
A supplier with two completely documented products ranked ahead of a supplier with none, regardless of overall reputation or website presentation. Strong testing on one item was never applied across an entire catalog.
04 — Lot-specific evidence
Batch and lot traceability mattered
An older batch with complete testing did not automatically validate a newer batch with an incomplete COA. A report for one product could not support another product simply because the ingredients were similar.
GLOW and KLOW share three components, but KLOW adds KPV. A complete KLOW report only verifies the tested KLOW lot; it cannot also qualify GLOW. During the Midwest Peptide review, the complete report belonged to KLOW. The separately published GLOW report lacked heavy-metals, endotoxin, and sterility testing, so Midwest GLOW was excluded.
05 — Finished products
How blends were handled
Blends were treated as their own products rather than substitutes for their individual components.
- Wolverine
- BPC-157 and TB-500 in a 1:1 ratio
- GLOW
- GHK-Cu, BPC-157, and TB-500
- KLOW
- GHK-Cu, BPC-157, TB-500, and KPV
A complete Wolverine COA did not automatically qualify standalone BPC-157 or TB-500. Likewise, a complete KLOW report did not qualify standalone KPV. For blends, the report also needed to identify the components and measure their individual amounts rather than provide only an unexplained total vial weight.
06 — Comparable counts
Avoiding inflated product counts
Multiple strengths produced from the same batch were not counted as separate products merely to increase a company’s qualifying total. One representative strength was counted when available strengths shared the same batch evidence. Creams, sprays, bacteriostatic water, and similar noncomparable items were excluded from peptide product counts and pricing comparisons.
07 — Independent checks
Independent report verification
Whenever possible, the vendor’s COA was checked against the issuing laboratory’s public verification system.
- Entering the report number into the laboratory’s database
- Checking a QR or search code
- Matching the product, vendor, lot, and report number
- Confirming that the laboratory record displayed the same analytical results
- Reviewing preserved report copies when a vendor replaced or removed an older document
External websites were used to verify laboratory evidence—not to replace the company’s own catalog or invent missing results.
08 — Living research
Why the list continues to change
COA coverage is a moving target. Vendors upload new reports, introduce new batches, and sometimes replace incomplete documents. Corrections were incorporated rather than hidden; accurate research requires updating conclusions when better batch-specific evidence becomes available.
- Midwest KPV initially lacked a qualifying report, but a new fully tested batch was later published.
- BioEdge KPV was first matched to an older incomplete report; a newer Kovera Labs COA was located and independently verified with all required panels.
- Midwest GLOW remained excluded because its current attached COA still lacked heavy-metals, endotoxin, and sterility results.
- KLOW remained separate and qualifying because its finished-product report contained the required testing.
09 — After qualification
How pricing was compared
Pricing was evaluated only after COA qualification. The popular-product comparison is a smaller view drawn from the broader master list—not the complete qualifying-product catalog.
- Selected a focused group of widely recognized products from the larger master list
- Used comparable strengths and formulas
- Counted only one strength per product
- Used regular prices rather than temporary sales or discount codes
- Excluded creams, sprays, bacteriostatic water, and unrelated formats
- Compared only companies with a qualifying COA for that specific product
- Identified the lowest and second available qualifying options
Dollar amounts are intentionally not published in the product directory. The researched lowest-price option appears first, followed by the remaining qualifying companies in the preserved comparison order. Researchers can open the supplier link for current details once those links are connected.
10 — Evidence limits
What a qualifying COA does—and does not—prove
A complete COA provides useful evidence about the sample submitted to the laboratory. It does not independently prove:
- The safety or effectiveness of a product
- Suitability for human or veterinary use
- FDA approval
- Complete manufacturing quality
- Unbroken chain of custody
- That every vial in a batch is identical
- That a future batch will produce the same results
Vendor-selected samples may provide less-independent evidence than anonymously purchased retail samples. The results are best understood as a documentation and transparency audit—not a medical recommendation or guarantee of product safety.
The central finding
Testing quality must be evaluated by product and by lot—not merely by company name.
A supplier may publish excellent documentation for one product and incomplete testing for another. Current batch matching, public verification, and complete analytical coverage matter more than broad statements such as “third-party tested” or “99% pure.”
Research snapshot updated September 1, 2026. All referenced products are marketed for research use only and are not approved for human or veterinary use. Blue Horizon Research updates conclusions when better product- and lot-specific evidence becomes available.